Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis
AbstractBackgrounds The available literature on the correlation between serum amyloid A (SAA) and prognosis of chronic kidney disease (CKD) are limited, and the findings from existing studies are inconclusive. This meta-analysis aimed to evaluate the available evidence regarding the link between SAA...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2250877 |
| _version_ | 1797211790705164288 |
|---|---|
| author | Li Li Hongli Liu Qinglin Zhang Hao Jin Hui Tao Rong Zhu Zhongwei Zhou |
| author_facet | Li Li Hongli Liu Qinglin Zhang Hao Jin Hui Tao Rong Zhu Zhongwei Zhou |
| author_sort | Li Li |
| collection | DOAJ |
| description | AbstractBackgrounds The available literature on the correlation between serum amyloid A (SAA) and prognosis of chronic kidney disease (CKD) are limited, and the findings from existing studies are inconclusive. This meta-analysis aimed to evaluate the available evidence regarding the link between SAA and risks of all-cause and cardiovascular mortality in CKD patients. Additionally, we aimed to investigate the potential dose-response relationships, provided that adequate data is accessible.Methods Pubmed and Embase were searched for related literature (last update: 12 July 2023). The pooled effect estimates were calculated using random- or fixed-effects models depending on heterogeneity among studies.Results This meta-analysis incorporated 8 studies encompassing 2331 CKD patients. The findings revealed an 85% increase in all-cause mortality risk [hazard risk (HR) 1.85, 95% confidence interval (CI) 1.29–2.65] and a 39% increase in cardiovascular mortality risk (HR 1.07, 95% CI 1.07–1.80) when comparing the highest tertile of baseline SAA levels to the lowest tertile. Furthermore, a positive linear relationship between SAA and all-cause mortality risk was observed (Pnon-linearity = 0.959), with a 17.7% increase in risk for each 10 mg/L SAA increase (HR 1.177, 95% CI 1.055–1.313). Similarly, a linear relationship between SAA and cardiovascular mortality risk was identified (Pnon-linearity = 0.477) with a 19.3% increase in risk for each 10 mg/L SAA increase (HR 1.193, 95% CI 1.025–1.388).Conclusions This meta-analysis provided evidence that SAA levels are positively and linearly associated with risks of all-cause and cardiovascular mortality among CKD patients. |
| first_indexed | 2024-03-11T23:44:42Z |
| format | Article |
| id | doaj.art-22328e13b2c14342a136dceecf8c1b5c |
| institution | Directory Open Access Journal |
| issn | 0886-022X 1525-6049 |
| language | English |
| last_indexed | 2024-04-24T10:32:05Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj.art-22328e13b2c14342a136dceecf8c1b5c2024-04-12T14:34:28ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492023-12-0145210.1080/0886022X.2023.2250877Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysisLi Li0Hongli Liu1Qinglin Zhang2Hao Jin3Hui Tao4Rong Zhu5Zhongwei Zhou6Department of Clinical Laboratory, Binhai County People’s Hospital, Binhai, ChinaDepartment of Clinical Laboratory, Nantong Tumor Hospital, Tumor Hospital Affiliated to Nantong University, ChinaDepartment of Blood Transfusion, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Jiangsu, ChinaDepartment of Blood Transfusion, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Jiangsu, ChinaDepartment of Blood Transfusion, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Jiangsu, ChinaDepartment of Clinical Laboratory, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, ChinaDepartment of Clinical Laboratory, Affiliated Hospital 6 of Nantong University, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People’s Hospital, Yancheng, ChinaAbstractBackgrounds The available literature on the correlation between serum amyloid A (SAA) and prognosis of chronic kidney disease (CKD) are limited, and the findings from existing studies are inconclusive. This meta-analysis aimed to evaluate the available evidence regarding the link between SAA and risks of all-cause and cardiovascular mortality in CKD patients. Additionally, we aimed to investigate the potential dose-response relationships, provided that adequate data is accessible.Methods Pubmed and Embase were searched for related literature (last update: 12 July 2023). The pooled effect estimates were calculated using random- or fixed-effects models depending on heterogeneity among studies.Results This meta-analysis incorporated 8 studies encompassing 2331 CKD patients. The findings revealed an 85% increase in all-cause mortality risk [hazard risk (HR) 1.85, 95% confidence interval (CI) 1.29–2.65] and a 39% increase in cardiovascular mortality risk (HR 1.07, 95% CI 1.07–1.80) when comparing the highest tertile of baseline SAA levels to the lowest tertile. Furthermore, a positive linear relationship between SAA and all-cause mortality risk was observed (Pnon-linearity = 0.959), with a 17.7% increase in risk for each 10 mg/L SAA increase (HR 1.177, 95% CI 1.055–1.313). Similarly, a linear relationship between SAA and cardiovascular mortality risk was identified (Pnon-linearity = 0.477) with a 19.3% increase in risk for each 10 mg/L SAA increase (HR 1.193, 95% CI 1.025–1.388).Conclusions This meta-analysis provided evidence that SAA levels are positively and linearly associated with risks of all-cause and cardiovascular mortality among CKD patients.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2250877Serum amyloid Achronic kidney diseaseall-cause mortalitycardiovascular mortalitydose-response relationshipmeta-analysis |
| spellingShingle | Li Li Hongli Liu Qinglin Zhang Hao Jin Hui Tao Rong Zhu Zhongwei Zhou Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis Renal Failure Serum amyloid A chronic kidney disease all-cause mortality cardiovascular mortality dose-response relationship meta-analysis |
| title | Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis |
| title_full | Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis |
| title_fullStr | Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis |
| title_full_unstemmed | Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis |
| title_short | Serum amyloid A and risks of all-cause and cardiovascular mortality in chronic kidney disease: a systematic review and dose-response meta-analysis |
| title_sort | serum amyloid a and risks of all cause and cardiovascular mortality in chronic kidney disease a systematic review and dose response meta analysis |
| topic | Serum amyloid A chronic kidney disease all-cause mortality cardiovascular mortality dose-response relationship meta-analysis |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2250877 |
| work_keys_str_mv | AT lili serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT hongliliu serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT qinglinzhang serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT haojin serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT huitao serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT rongzhu serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis AT zhongweizhou serumamyloidaandrisksofallcauseandcardiovascularmortalityinchronickidneydiseaseasystematicreviewanddoseresponsemetaanalysis |